Overview Eplerenone for the Treatment of Central Serous Chorioretinopathy Status: Completed Trial end date: 2015-05-01 Target enrollment: Participant gender: Summary To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy . Phase: N/A Details Lead Sponsor: Wills EyeCollaborator: Mid Atlantic RetinaTreatments: EplerenoneSpironolactone